A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Status:
Completed
Trial end date:
2020-07-10
Target enrollment:
Participant gender:
Summary
Chemotherapy regimens for pancreatic cancer can now stabilize a patient's cancer and/or place
some patients in remission or partial remission. The challenge now is to find options for
maintenance therapies that will improve survival and allow continued benefits with minimal
toxicities and inconvenience to the patients. This study will determine the effects of one
possible maintenance regimen.
The study is being conducted to determine the effects that pembrolizumab with or without the
addition of paricalcitol may have on pancreatic cancer. Half of the patients will be
randomized to receive pembrolizumab + paricalcitol and half to receive pembrolizumab +
placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Genomics Research Institute
Collaborators:
Merck Sharp & Dohme Corp. Stand Up To Cancer
Treatments:
Ergocalciferols Pembrolizumab Retinol palmitate Vitamin A Vitamin D Vitamins